Research compound
CJC-1295 with DAC
A long-acting growth-hormone-releasing hormone analogue studied in adults.
Also discussed as: CJC1295 · Drug Affinity Complex
THE RESEARCH QUESTION
What is being investigated?
Human studies measured growth hormone and IGF-I responses. DAC changes the compound’s duration of action.
EVIDENCE SNAPSHOT
Human hormone studies
Hormone concentrations increased in early studies. That is not evidence of longer life, better recovery or a favourable long-term benefit–risk balance in healthy people.
LIMITS & SAFETY
What should you know?
Heart-rate and vascular reactions have been reported.
FOLLOW THE EVIDENCE
Sources & further reading
- CJC-1295: GH and IGF-I study in healthy adults (2006) ↗Human study
- FDA: safety information for bulk substances used in compounding ↗Regulator
Checked 8 October 2026. Sources may describe different populations, formulations and jurisdictions. This overview is not a systematic review or individual medical advice.
PUT THE EVIDENCE IN CONTEXT
Questions about what you’ve read?
Request an educational conversation with Matthew about the evidence and questions to raise with your medical professional.